Breast cancer study halted

June 20, 2007

The U.S. National Cancer Institute halted a $100 million study of drugs designed to prevent breast cancer in women at risk for the disease.

The study couldn't be justified amid questions of cost, safety and overall benefit, the institute announced Tuesday.

The dangers of introducing these drugs, with their many known side effects, outweighs their potential," the institute said.

While proponents argued the study was crucial to determining the best drugs to prevent breast cancer, other advocacy groups called for more research to better identify women who would benefit most.

The study would have tested a new generation of drugs known as aromatase inhibitors, The Washington Post reported Wednesday. Under the study, about 12,800 women in the United States and Canada would have received raloxifene or the aromatase inhibitor letrozole.

About 180,000 American women are diagnosed with breast cancer each year and about 40,000 die from the disease, making breast cancer the second most common cancer in women.

Copyright 2007 by United Press International

Explore further: For women with genetic risk, bi-annual MRI beats mammograms

Related Stories

For women with genetic risk, bi-annual MRI beats mammograms

December 8, 2017
Intensive surveillance including a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) exam every six months was far more effective in detecting breast cancer in younger women with a high-risk genetic profile than ...

Postmenopausal women who lose weight may have reduced breast cancer risk

December 8, 2017
Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to data presented at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5–9.

New breast cancer drug may benefit younger women, too

December 6, 2017
(HealthDay)—Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found.

Biological factors don't fully explain racial disparities for breast cancer type

December 7, 2017
Higher risk of recurrence for black women with hormone receptor-positive, HER2-negative breast cancer compared with white women cannot be completely explained by underlying biological factors, University of North Carolina ...

Screening has had 'little impact' on falling breast cancer deaths in the Netherlands

December 5, 2017
Breast screening in the Netherlands seems to have had a marginal effect on breast cancer mortality over the past 24 years, suggests research in The BMJ today.

Older women with HR-positive breast cancer may receive similar benefit from CDK 4/6 inhibitors as younger women

December 8, 2017
Older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6) achieved progression-free survival at a rate similar to that ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.